Incyte Corporation  

(Public, NASDAQ:INCY)   Watch this stock  
Find more results for Incyte Corporation�
101.38
-5.96 (-5.55%)
After Hours: 100.99 -0.39 (-0.38%)
Apr 27, 7:58PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 100.63 - 107.84
52 week 43.44 - 111.93
Open 107.42
Vol / Avg. 0.00/1.19M
Mkt cap 18.58B
P/E     -
Div/yield     -
EPS -0.33
Shares 171.77M
Beta 1.00
Inst. own 97%
May 22, 2015
Incyte Corp Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 19, 2015
Incyte Corp at UBS Global Healthcare Conference - 3:00PM EDT - Add to calendar
May 14, 2015
Incyte Corp at Bank of America Merrill Lynch Health Care Conference - 11:00AM EDT - Add to calendar
May 7, 2015
Incyte Corp at Deutsche Bank Health Care Conference - 10:00AM EDT - Add to calendar
Apr 30, 2015
Q1 2015 Incyte Corp Earnings Call - 8:00AM EDT - Add to calendar
Apr 30, 2015
Q1 2015 Incyte Corp Earnings Release - 7:00AM EDT - Add to calendar
Apr 20, 2015
Incyte Corp. AACR Investor Meeting Event - Webcast
Mar 11, 2015
Incyte Corp at Barclays Healthcare Conference
Mar 3, 2015
Incyte Corp at Cowen Health Care Conference
Feb 23, 2015
Incyte Corp at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -29.80% -9.48%
Operating margin -20.67% -0.94%
EBITD margin - 0.06%
Return on average assets -18.35% -6.64%
Return on average equity - -
Employees 588 -
CDP Score - -

Address

1801 Augustine Cut off
WILMINGTON, DE 19803-4404
United States - Map
+1-302-4986700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company�s compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received development and commercialization rights for the compound for inflammatory and autoimmune diseases.

Officers and directors

Richard U. De Schutter Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Herve Hoppenot President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Julian C. Baker Independent Vice Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
David W. Gryska Chief Financial Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Reid M. Huber Executive Vice President, Chief Scientific Officer
Age: 43
Bio & Compensation  - Reuters
Eric H. Siegel Executive Vice President, General Counsel
Age: 50
Bio & Compensation  - Reuters
Paula J. Swain Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
James M. Daly Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Barry P. Flannelly Executive Vice President - Business Development and Strategic Planning
Age: 57
Bio & Compensation  - Reuters
Richard S. Levy M.D. Executive Vice President, Chief Drug Development and Medical Officer
Age: 57
Bio & Compensation  - Reuters